Louis-Charles Fortier

Prix et distinctions

• (2021) Pharmacology prize / Prix de Pharmacologie (Prize given by the students of Pharmacology to recognize the quality of my teaching). Université de Sherbrooke. (Prix).
• (2017) Pharmacology prize / Prix de Pharmacologie (Prize given by the students of Pharmacology to recognize the quality of my teaching). Université de Sherbrooke. (Prix).
• (2016) Junior 2 Salary Award. Fonds de recherche du Québec - Santé (FRQS). (Prix).
• (2012) Junior 1 Salary Award. Fonds de recherche du Québec - Santé (FRQS). (Prix).
• (2008) Salary award from the CRCHUS. Centre de recherche clinique Étienne-Le Bel. (Prix).
• (2007) Postdoc scholarship. CRMUS. (Prix).
• (2000) PhD Scholarship. Fondation des Gouverneurs - Agriculture Canada (CRDA, St-Hyacinthe). (Prix).
• (1999) PhD scholarship. FCAR. (Prix).
• (1998) First prize-oral competition-biotechnology. Institute of Food Technology. (Prix).
• (1997) PhD Scholarship from the French Government. French Government. (Prix).
• (1996) M.Sc. Scholarship. Medical Research Council of Canada. (Prix).
• (1995) M.Sc. Scholarship. Faculty of medicine of the Université de Sherbrooke. (Prix).

Financement

• Subvention. (En cours d’évaluation). Candidat principal. Demystifying virus-host interactions in Clostridioides difficile through genetic engineering of bacteriophages and the bacterial S-layer. Instituts de Recherche en Santé du Canada (IRSC). Projet. 1 295 000 $. (2004-2029)
• Subvention. (Obtenu). Cocandidat. Understanding the interplay between Shp-2 and microbiota in colonic inflammation. Instituts de Recherche en Santé du Canada (IRSC). Project. 994 500 $. (2024-2029)
• Subvention. (En cours d’évaluation). Chercheur principal. Leveraging nanopore sequencing technology of whole Escherichia coli genomes to tailor antibiotherapy and development of phage-based applications to treat urinary tract infections. Sanofi. iDEA-TECH. 149 800 $. (2024-2026)
• Subvention. (En cours d’évaluation). Candidat principal. Phage therapy targetting proinflammatory bacteria associated with ulcerative colitis. University of Toronto. Canada Wide Bacteriophage Therapy Acceleration Fund. 50 000 $. (2024-2026)
• Subvention. (Obtenu). Cocandidat. Development of an anodised aluminum surface for virucidal, bactericidal and sporicidal applications / Développement d'une surface d'aluminium anodisé pour des applications virucides, bactéricides et sporicides.. Conseil de Recherches en Sciences Naturelles et Génie du Canada (CRSNG). Programme de recherche orienté en partenariat/Production et transformation de l'AI. 609 000 $. (2022-2025)
• Subvention. (Obtenu). Candidat principal. Demystifying virus-host interactions in Clostridioides difficile through genetic engineering of bacteriophages and the bacterial S-layer. Instituts de Recherche en Santé du Canada (IRSC). Project grant. 100 000 $. (2024-2025)
• Subvention. (Obtenu). Chercheur principal. Phage-host interactions in pathogenic and commensal clostridia. Conseil de Recherches en Sciences Naturelles et Génie du Canada (CRSNG). Discovery. 180 000 $. (2020-2025)
• Subvention. (Obtenu). Cocandidat. Epithelial-specific role of SOCS1 in prevention of intestinal inflammation. Instituts de Recherche en Santé du Canada (IRSC). Projet. 787 950 $. (2019-2024)
• Subvention. (Obtenu). Candidat principal. Replacement for Anaerobic Workstations. Conseil de Recherches en Sciences Naturelles et Génie du Canada (CRSNG). Research Tools and Instruments. 145 503 $. (2023-2024)
• Contrat. (Terminé). Chercheur principal. Évaluation de la solubilité, de la stabilité, et de l'efficacité antibactérienne du PER-OXY supplémenté de 5 additifs chimiques. Kalium Solutions Inc.. N/A. 14 000 $. (2022-2023)
• Subvention. (Terminé). Cochercheur. Development of a synthetic bacterium to fight persistent Gram-positive bacterial infecitons / Développement d’une bactérie synthétique pour lutter contre les infections persistantes à Gram-positif. Centre de recherche du CHUS. Programme de projets structurants. 74 980 $. (2021-2022)
• Subvention. (Terminé). Cochercheur. Évaluation de l'efficacité des probiotiques sur les affections post-COVID-19. Instituts de Recherche en Santé du Canada (IRSC). Emergig COVID-19 Research Gaps & Priorities - Post COVID-19 condition. 997 273 $. (2021-2022)
• Subvention. (Terminé). Cochercheur. Initial vancomycin taper for the prevention of recurrent Clostridium difficile infection. Instituts de Recherche en Santé du Canada (IRSC). Projet. 378 676 $. (2019-2021)
• Subvention. (Terminé). Chercheur principal. A3S Anodized aluminum: a virucidal surface to fight the COVID-19 pandemic in hospitals, LTCF and public areas / L'Aluminium anodisé A3S : une surface virucide pour lutter contre la pandémie de COVID-19 dans les hôpitaux les CHSLD et les lieux publics. Conseil de Recherches en Sciences Naturelles et Génie du Canada (CRSNG). Alliance - Covid. 50 000 $. (2020-2021)
• Contrat. (Terminé). Chercheur principal. Anodized aluminum-based biocidal surfaces to fight bacterial and viral infections / Surfaces biocides à base d’aluminium anodisé afin de combattre les infections bactériennes et virales. A3 Surfaces Inc.. N/A. 11 830 $. (2020-2021)
• Contrat. (Terminé). Cocandidat. Anodized aluminum-based biocidal surface to fight viral infections / Surface biocide à base d’aluminium anodisé afin de combattre les infections virales. Centre québécois de recherche et de développement de l'aluminium (CQRDA). Québec-Innove. 100 000 $. (2020-2020)
• Subvention. (Terminé). Chercheur principal. Phage biology and diversity in Clostridium difficile and other commensal clostridia. (2015-2020)
• Subvention. (Terminé). Cocandidat. Replacement for Microbial Growth Assay Cluster. Conseil de Recherches en Sciences Naturelles et Génie du Canada (CRSNG). Research Tools and Instruments. 143 350 $. (2019-2020)
• Subvention. (Terminé). Cocandidat. Impact de la concentration en métalloprotéinases 1-2-8-9, d’Enterococcus faecalis, de Pseudomonas aeruginosa et de Klebsiella sur le taux de fuite pancréatique post Whipple.. Centre de Recherche du Centre Hospitalier de l'Université de Sherbrooke Inc. (CRCHUS) (Sherbrooke, QC). Programme de financement interne. 25 000 $. (2018-2020)
• Subvention. (Terminé). Chercheur principal. Setup and validation of the methodology for virome analysis. / Mise en place et validation de la méthodologie pour l’analyse du virome. Centre de recherche du CHUS. Inflammation-Pain research axis. 16 250 $. (2018-2019)
• Subvention. (Terminé). Chercheur principal. Isolation and characterization of Clostridium perfringens lytic phages for veterinary applications in the poultry industry. Conseil de Recherches en Sciences Naturelles et Génie du Canada (CRSNG). Engage. 25 000 $. (2018-2019)
• Subvention. (Terminé). Cochercheur. Développement d'un modèle animal de déclenchement du travail par modification du microbiote intestinal pour une meilleure compréhension des facteurs impliqués dans la prématurité. Fondation des étoiles (La) (Qc). Fondation des étoles. 10 000 $. (2017-2019)
• Subvention. (Terminé). Cochercheur. Microbiote intestinal en grossesse et prématurité. Centre de recherche du CHUS. Programme d'Aide au Financement de la Recherche (PAFI). 25 000 $. (2017-2019)
• Subvention. (Terminé). Cocandidat. Replacement for Fast Protein Liquid Chromatography System. Conseil de Recherches en Sciences Naturelles et Génie du Canada (CRSNG). Research Tools and Instruments. 138 000 $. (2018-2019)
• Subvention. (Terminé). Cocandidat. Rôle intrinsèque de SOCS1 dans l’épithélium intestinal et l'inflammation. Centre de recherche en inflammation et oncologie digestive de l’UdeS. operating grant. 15 000 $. (2017-2018)
• Subvention. (Terminé). Cochercheur. Prophylactic and therapeutic use of chenodeoxycholic acid (CDCA) against Clostridium difficile infection. Centre de recherche du CHUS. PAFI (internal funding program). 25 000 $. (2016-2018)
• Subvention. (Terminé). Chercheur principal. Gene expression control by riboswitches: mechanism and role in C. difficile biology and virulence. (2014-2017)
• Contrat. (Terminé). Chercheur principal. Therapeutic and prophylactic potential of egg yolk antibodies in the fight against Clostridium difficile infections. Immune Biosolutions inc.. Collaborative research contract. 33 574 $. (2015-2016)
• Subvention. (Terminé). Chercheur principal. Anti-Clostridium difficile mechanisms of action of BioK+ probiotics - Étude des mécanismes d’action anti-Clostridium difficile par le probiotique Bio-K+. (2015-2015)
• Subvention. (Terminé). Chercheur principal. Phage biology and diversity in Clostridium difficile. (2010-2015)
• Subvention. (Terminé). Chercheur principal. Anti-Clostridium difficile mechanisms of action of BioK+ probiotics - Étude des mécanismes d’action anti-Clostridium difficile par le probiotique Bio-K+. (2014-2015)
• Subvention. (Terminé). Chercheur principal. Development of specific antibodies targeting the toxins, cell surface proteins, and spores of C. difficile - Développement d’anticorps spécifiques dirigés contre des protéines de surface des bactéries et des spores de C. difficile et ses toxines. (2013-2014)
• Subvention. (Terminé). Cochercheur. Development of a new class of antibiotics targeting the guanine riboswitch to fight C. difficile infections - Développement d'une nouvelle classe d'antibiotiques ciblant le riborégulateur guanine pour le traitement des infections à C. difficile. (2012-2014)
• Subvention. (Terminé). Cochercheur. Genetic, transcriptional and functional study of c-di-GMP signaling in C. difficile. - Signalisation cellulaire par le c-diGMP chez Clostridium difficile : étude génétique, transcriptionnelle et fonctionnelle. (2010-2013)
• Subvention. (Terminé). Chercheur principal. Study on how tigecycline affects the microbiota and bile acid composition of the gut and how it impacts Clostridium difficile lifestyle and susceptibility to Clostridium difficile infection. (2011-2012)
• Subvention. (Terminé). Chercheur principal. Role of the post-transcriptional regulator Hfq in virulence of Clostridium difficile - Rôle du régulateur post-transcriptionnel Hfq dans la virulence de Clostridium difficile. (2010-2011)
• Subvention. (Terminé). Chercheur principal. Impact of sub-inhibitory concentrations of antibiotics on sporulation of Clostridium difficile. (2009-2011)
• Subvention. (Terminé). Chercheur principal. Étude moléculaire des bactériophages infectant Clostridium difficile et développement d'alternatives thérapeutiques pour traiter la diarrhée associée à C. difficile (DACD). (2008-2011)
• Subvention. (Terminé). Chercheur principal. Platform for studying virulence factors in anaerobic pathogens and for the development of phage-based therapeutic agents. (2010-2011)
• Subvention. (Terminé). Chercheur principal. Mobile genetic elements from Clostridium difficile and development of molecular tools for its genetic manipulation. (2007-2010)
• Subvention. (Terminé). Cochercheur. Modulation des profils d'expression génique causée par les toxines du C. difficile dans les cellules de côlon. (2009-2009)
• Subvention. (Terminé). Cochercheur. Modulation des profils d'expression génique causée par les toxines du C. difficile dans les cellules de côlon. (2007-2009)
• Subvention. (Terminé). Chercheur principal. Development of phage therapy and phage-derived therapeutic molecules to treat Clostridium difficile-associated diarrhea.. (2007-2009)
• Subvention. (Terminé). Chercheur principal. Développement de la phagothérapie et de molécules thérapeutiques dérivées des bactériophages pour traiter la diarrhée associée à Clostridium difficile. (2007-2009)
• Subvention. (Terminé). Chercheur principal. Étude de la sporulation chez Clostridium difficile et impact sur l'épidémiologie des diarrhées associées à C. difficile (DACD).. (2008-2008)

Publications

Articles de revue

• Dong, Q; Harper, S; McSpadden, E; Son, SS; Allen, MM; Lin, H; Smith, RC; Metcalfe, C; Burgo, V; Woodson, C; Sundararajan, A; Rose, A; McMillin, M; Moran, D; Little J; Mullowney, M; Sidebottom, AM; Fortier, LC; Shen A; Pamer, EG. (2024). Clostridioides difficileProtection against disease by a naturally avirulent strain. Cell Host & Microbe (Article soumis).
• *Saunier, M; Fortier, LC; Soutourina, O. (2024). RNA-based regulation in bacteria-phage interactions. Anaerobe 87 102851. (Article publié).
• *Jann, J; *Gascon, S; Fradette, J; Auclair-Gilbert, M; Soucy, G; Fortier, LC***; Faucheux, N*** (***Co-corresponding). (2023). Assessment of antibacterial properties and skin irritation potential of anodized aluminum impregnated with various quaternary ammonium. Biomaterials Advances Volume 150 (July 2023), 1-17. (Article publié).
• Dong Q, Lin H, *Allen MM, *Garneau JR, Sia JK, Smith RC, Haro F, McMillen T, Pope RL, Metcalfe C, Burgo V, Woodson C, Dylla N, Kohout C, Sundararajan A, Snitkin ES, Young VB, Fortier LC, Kamboj M, Pamer EG. (2023). Clostridioides difficile.Virulence and genomic diversity among clinical isolates of ST1 (BI/NAP1/027). Cell Reports 42 (8), 112861. (Article publié).
• *Royer ALM, *Umansky AA, *Allen MM, *Garneau JR, *Ospina-Bedoya M, Kirk JA, Govoni G, Fagan RP, Soutourina O, Fortier LC. (2023). Clostridioides difficileThe S-Layer Protein A (SlpA) serves as a general phage receptor. Microbiology Spectrum Feb 15;e0389422 1-15. (Article publié).
• /*Umansky AA, Fortier LC. (2023). Clostridioides difficileThe long and sinuous road to phage-based therapy of infections. Frontiers in Medicine 10 1-8. (Article publié).
• Granger, MF; Kelly, M; Fortier, LC; Founier, E; Cote-Gravel, J; Malouin, F; Valiquette, L; Lévesque, S. (2023). KlebsiellaChronic diarrhea caused by toxin producer following antibiotic associated hemorrhagic colitis: successful treatment by faecal microbiota transplant. Clinical Infectious Diseases 436 1-4. (Article publié).
• Wilson J, Fortier LC, Fagan R, Bullough P. (2023). Molecular mechanism of bacteriophage tail contraction-structure of an S-layer-penetrating bacteriophage. Nature Communications NA NA. (Article soumis).
• Aissou, T; *Jann, J; Faucheux, N; Fortier, LC; Braidy, N; Veilleux, J. (2023). Suspension Plasma Sprayed Copper-graphene Coatings for Improved AntibacterialProperties. Applied Surface Science 639 1-10. (Article publié).
• Dong Q, Lin H, Allen MM, Garneau JR, Sia JK, Smith RC, Haro F, McMillen T, Pope RL, Metcalfe C, Burgo V, Woodson C, Dylla N, Kohout C, Sundararajan A, Snitkin ES, Young VB, Fortier LC, Kamboj M, Pamer EG. (2022). Clostridioides difficileVirulence and genomic diversity among clinical isolates of ST1 (BI/NAP1/027). BioRxiv doi: 10.1101/2023.01 1-48. (Article publié).
• Valdes, Jennifer Gagné‐Sansfaçon, J; Reyes, V; Armas, A; Marrero, G; Moyo‐Muamba, M; Ramanathan, S; Perreault, N; Ilangumaran, S; Rivard, N; Fortier, LC; Menendez, A. (2022). Defects in the expression of colonic host defense factors associate with barrier dysfunction induced by a high‐fat/high‐cholesterol diet. The Anatomical Record doi:10.1002/ 1-19. (Article publié).
• Kautzman, AM; Faida Mobulakani, JM; Marrero Cofino, G; Irmine Quenum, AJ; Armas Cayarga, A; Asselin, C; Fortier, LC; Ilangumaran, S; Menendez, A; Ramanathan, S. (2022). Interleukin 15 in murine models of colitis. The Anatomical Record doi:10.1002/a 1-20. (Article publié).
• *Smith-Peter, E; *Lalonde Séguin, D; *St-Pierre, E; *Sekulovic, O; Jeanneau, S; Tremblay-Tétreault, C; Lamontagne, A-M; Jacques, P-E; Lafontaine, D A; Fortier, L-C. (2021). Clostridioides difficileInactivation of the riboswitch-controlled GMP synthase GuaA in is associated with severe growth defects and poor infectivity ina mouse model of infection. RNA Biology 18 (2), 699-710. (Article publié).
• Heuler, J; Fortier, LC; Sun, X. (2021). Clostridioides difficile Phage Biology and Application. FEMS Microbiology Reviews 45 (5), fuab012. DOI. (Article publié).
• *Garneau, JR; Legrand, V; Marbouty, M; Press, MO; Vik, DR; Fortier, LC; Sullivan, MB; Bikard, D; Monot, M. (2021). High-throughput identification of viral termini and packaging mechanisms in virome datasets using PhageTermVirome. Scientific Reports 11 (1), 18319. (Article publié).
• Bouchard, ME; Rousseau, E; Fortier, LC; Girard, I. (2021). Pathophysiology of Vaginal Erosions in Women Using Pessary: a pilot study examining vaginal microbiota. J Obstet Gynaecol Can S1701-2163 (21), 00347-9. DOI. (Article publié).
• *Jann ,J; Drevelle, O; Chen, XG; Auclair-Gilbert, M; Soucy, G; Faucheux, N; Fortier, LC. (2021). Rapid antibacterial activity of anodized aluminum-based materials impregnated with quaternary ammonium compounds for high-touch surfaces to limit transmission of pathogenic bacteria. RSC Advances 11 38172–38188. (Article publié).
• Peltier, J; Hamiot, A; *Garneau, JR; Boudry, P; Maikova, A; Hajnsdorf, E; Fortier, LC; Dupuy, B; Soutourina, O. (2020). Clostridioides difficileType I toxin-antitoxin systems contribute to the maintenance of mobile genetic elements in. Communications Biology 3 (1), 718. (Article publié).
• Selle K, Fletcher J, Tuson H, Schmitt D, McMillan L, Vridhambal G, Rivera A, Montgomery S, Fortier LC, Barrangou R, Theriot C, Ousterout D. (2020). In vivo targeting of using phage-delivered CRISPR-Cas3 antimicrobials. mBio 11 (2), e00019-20. (Article publié).
• *Garneau JR, Abou Chakraa CN, Fortier LC, Labbé AC, Simor AE, Gold W, Muller M, McGeer A, Powis J, Katz K, Pépin J and L Valiquette. (2019). Clostridioidis difficileMultilocus Variable-Number Tandem-Repeat Analysisof Clustersin Ribotype 027 Isolates and Lack of Association with Clinical Outcomes. Journal of Clinical Microbiology 26 (57), e01724-18. (Article publié).
• Fortier, LC. (2018). Clostridioides (Clostridium) difficileBacteriophages contribute to shaping species. Frontiers in Microbiology (commissioned article) 9 2033. (Article publié).
• Yan LH, Le Roux A, Boyapelly K, Lamontagne AM, Archambault MA, Picard-Jean F, *Lalonde-Seguin D, *St-Pierre E, Najmanovich RJ, Fortier LC, Lafontaine D, Marsault É. (2018). Clostridioides difficilePurine analogs targeting the guanine riboswitch as potential antibiotics against . European Journal of Medicinal Chemistry 143 755-757. (Article publié).
• Carignan A (Corr. author), Fortier LC. (2018). Discovery of keyicin, a new antibiotic: it takes two to tango. Médecine/Sciences 34 (5), 377-379. (Article publié).
• *Garneau J, *Sekulovic O, Dupuy B, Soutourina O, Monot M, Fortier LC. (2018). High Prevalence and Genetic Diversity of Large phiCD211 (phiCDIF1296T)-Like Prophages in Clostridioides difficile. Applied and Environmental Microbiology 84 (3), e02164-17. (Article publié).
• Allard M, Bergeron J, Baharnoori M, Srivastava L, Fortier LC, Poyart C, Sébire G. (2017). A sexually dichotomous, autistic-like phenotype is induced by Group B Streptococcus maternofetal immune activation. Autism Research 10 (2), 233-245. (Article publié).
• Tremblay S,Côté NML*, Grenier G, Duclos-Lasnier G, Fortier LC, Ilangumaran S, Menendez A. (2017). Ileal antimicrobial peptide expression is dysregulated in old age. Immunity & Aging 14 (19), 1-5. (Article publié).
• *Garneau JR, Depardieu F, Fortier LC, Bikard D, Monot M. (2017). PhageTerm: a tool for fast and accurate determination of phage termini and packaging mechanism using next-generation sequencing data. Scientific Reports 7 1-10. (Article publié).
• Bergeron J, Gerges N, Guiraut C, Djordje Grbic, Allard MJ, Fortier LC, Vaillancourt C, Sébire G. (2016). Activation of the IL-1?/CXCL1/MMP-10 axis in chorioamnionitis induced by inactivated Group B Streptococcus. Placenta 47 116-123. (Article publié).
• Abou Chakra CN, McGeer A, Labbé AC, Simor AE, Gold WL, Muller MP, Powis J, Katz K, *Garneau JR, Fortier LC, Pépin J, Cadarette SM, Valiquette L. (2015). Clostridium difficileFactors Associated With Complications of Infection in a Multicenter Prospective Cohort. Clinical Infectious Diseases 61 (12), 1781-1788. (Article publié).
• Boudry P, Semenova E, Monot M, Datsenko KA, Lopatina A, *Sekulovic O, *Ospina-Bedoya M, Fortier LC, Severinov K, Dupuy B, Soutourina O. (2015). Clostridium difficileFunction of the CRISPR-Cas System of the Human Pathogen . mBio 6 (5), e01112-15. (Article publié).
• *Sekulovic O, *Ospina Bedoya M, Fivian-Hughes AS, Fariweather NF, Fortier LC. (2015). Clostridium difficileThe Cell Wall Protein CwpV Confers Phase-Variable Phage Resistance. Molecular Microbiology 98 (2), 329-342. (Article publié).
• Bordeleau E, Purcell EB, Lafontaine DA, Fortier LC, Tamayo R, Burrus V. (2015). Cyclic-di-GMP riboswitch-regulated type IV pili contribute to aggregation of Clostridium difficile. Journal of Bacteriology 197 (5), 819-832. (Article publié).
• Bergeron J, Deslauriers J, Grignon S, Fortier LC, Lepage M, Stroh T, Poyart C, Sébire G. (2015). Exposition to group B streptococcal maternalinflammation: White matter injury and autistic-like behavior predominantlyaffecting male rat offspring. Int J Dev Neurosci 47 (A), 47-48. (Article publié).
• *Sekulovic O, Fortier LC. (2015). Global transcriptional response of Clostridium difficile carrying the ?CD38-2 prophage. Applied and Environmental Microbiology 81 (4), 1364-1374. (Article publié).
• Allard MJ, Bergeron J, Grbic D, Fortier LC, Poyart C, Sébire G. (2015). StreptococcusGroup B infection during gestation induces gender specific neurodevelopmentalimpairments. Int J Dev Neurosci 61 (12), 86. (Article publié).
• *Sekulovic O, *Garneau JR, *Néron A, Fortier LC. (2014). Characterization of Temperate Phages Infecting Clostridium difficile Isolates from Human and Animal Origin. Applied and environmental microbiology 80 (8), 2555-2563. (Article publié).
• *Garneau JR, Valiquette L, Fortier LC. (2014). Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam. BMC infectious diseases 14 (1), 29. (Article publié).
• Fortier LC, *Sekulovic O. (2013). Importance of prophages to evolution and virulence of bacterial pathogens. Virulence 4 (5), 354-365. (Article publié).
• Bergeron JD , Deslauriers J , Grignon S , Fortier LC , Lepage M , Stroh T , Poyart C , Sébire G. (2013). White matter injury and autistic-like behavior predominantly affecting male rat offspring exposed to group B streptococcal maternal inflammation. Developmental neuroscience 35 (6), 504-515. (Article publié).
• *Meessen-Pinard M , *Sekulovic O , Fortier LC. (2012). Evidence of in vivo prophage induction during Clostridium difficile infection. Applied and environmental microbiology 78 (21), 7662-7670. (Article publié).
• Gebhart D , Williams SR , Bishop-Lilly KA , Govoni GR , Willner KM , Butani A , Sozhamannan S , Martin D , Fortier LC , Scholl D. (2012). Novel high-molecular-weight, R-type bacteriocins of Clostridium difficile. Journal of bacteriology 194 (22), 6240-6247. (Article publié).
• *Sirard S , Valiquette L , Fortier LC. (2011). Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes. Journal of clinical microbiology 49 (12), 4040-4046. (Article publié).
• *Sekulovic O , *Meessen-Pinard M , Fortier LC. (2011). Prophage-stimulated toxin production in Clostridium difficile NAP1/027 lysogens. Journal of bacteriology 193 (11), 2726-2734. (Article publié).
• Bordeleau E , Fortier LC , Malouin F , Burrus V. (2011). c-di-GMP turn-over in Clostridium difficile is controlled by a plethora of diguanylate cyclases and phosphodiesterases. PLoS genetics 7 (3), e1002039. (Article publié).
• Gonzales M , Pepin J , Frost EH , Carrier JC , Sirard S , Fortier LC , Valiquette L. (2010). Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. BMC infectious diseases 10 (Article publié).
• Mulhbacher J , Brouillette E , Allard M , Fortier LC , Malouin F , Lafontaine DA. (2010). Novel riboswitch ligand analogs as selective inhibitors of guanine-related metabolic pathways. PLoS pathogens 6 (4), e1000865. (Article publié).
• Matte I , Lane D , Côté E , Asselin AE , Fortier LC , Asselin C , Piché A. (2009). Antiapoptotic proteins Bcl-2 and Bcl-XL inhibit Clostridium difficile toxin A-induced cell death in human epithelial cells. Infection and immunity 77 (12), (Article publié).
• Haaber J , Moineau S , Fortier LC , Hammer K. (2008). AbiV, a novel antiphage abortive infection mechanism on the chromosome of Lactococcus lactis subsp. cremoris MG1363. Applied and environmental microbiology 74 (21), (Article publié).
• Fortier LC , Moineau S. (2007). Morphological and genetic diversity of temperate phages in Clostridium difficile. Applied and environmental microbiology 73 (22), (Article publié).
• Fortier LC , Bransi A , Moineau S. (2006). Genome sequence and global gene expression of Q54, a new phage species linking the 936 and c2 phage species of Lactococcus lactis. Journal of bacteriology 188 (17), (Article publié).
• Girard H, Villeneuve L, Court MH, Fortier LC, Caron P, Hao Q, von Moltke LL, Greenblatt DJ, Guillemette C. (2006). The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. Drug metabolism and disposition: the biological fate of chemicals 34 (7), (Article publié).
• Fortier LC , Bouchard JD , Moineau S. (2005). Expression and site-directed mutagenesis of the lactococcal abortive phage infection protein AbiK. Journal of bacteriology 187 (11), (Article publié).
• Girard H , Thibaudeau J , Court MH , Fortier LC , Villeneuve L , Caron P , Hao Q , von Moltke LL , Greenblatt DJ , Guillemette C. (2005). UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver. Hepatology (Baltimore, Md.) 42 (2), (Article publié).
• Girard H , Court MH , Bernard O , Fortier LC , Villeneuve L , Hao Q , Greenblatt DJ , von Moltke LL , Perussed L , Guillemette C. (2004). Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 14 (8), (Article publié).
• Fortier LC , Tourdot-Maréchal R , Diviès C , Lee BH , Guzzo J. (2003). Induction of Oenococcus oeni H+-ATPase activity and mRNA transcription under acidic conditions. FEMS microbiology letters 222 (2), (Article publié).
• Villeneuve L , Girard H , Fortier LC , Gagné JF , Guillemette C. (2003). Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. The Journal of pharmacology and experimental therapeutics 307 (1), (Article publié).
• Guzzo J , Jobin MP , Delmas F , Fortier LC , Garmyn D , Tourdot-Maréchal R , Lee B , Diviès C. (2000). Regulation of stress response in Oenococcus oeni as a function of environmental changes and growth phase. International journal of food microbiology 55 (1-3), (Article publié).
• Tourdot-Maréchal R , Fortier LC , Guzzo J , Lee B , Diviès C. (1999). Acid sensitivity of neomycin-resistant mutants of Oenococcus oeni: a relationship between reduction of ATPase activity and lack of malolactic activity. FEMS microbiology letters 178 (2), (Article publié).
• Fortier LC , Delbecchi L , Bourgaux-Ramoisy D , Bourgaux P. (1998). Rescue of polyomavirus DNA after co-transfection of recombinant plasmids with viral DNA fragments. Biochimica et biophysica acta 1395 (1), (Article publié).

Chapitres de livre

• Fortier, LC. (2017). The contribution of bacteriophages to the biology and virulence of pathogenic clostridia. Gadd GM, Sariaslani S. Advances in Applied Microbiology (Commissioned chapter) (101, 1-10). Pays-Bas : Elsevier. (Article publié).
• *Sekulovic O, Fortier LC. (2016). Characterization of functional prophages in Clostridium difficile. Adam Roberts and Peter Mullany. Methods in Molecular Biology - Clostridium difficile. (Commissioned chapter) (476, 143-65). Royaume-Uni : Humana Press. (Article publié).
• Fortier LC, Moineau S. (2009). Phage production and maintenance of stocks, including expected stock lifetimes. Clokie MRJ and Kropinski AM. Methods in Molecular biology (501, 203-219). États-Unis d'Amérique : Clokie MRJ and AM Kropinski. (Article publié).

Articles de conférence

• *Royer A, *Umansky A, Fagan RP, Soutourina O, Fortier LC. (2023). ClostridioidesUnravelling the interaction specificity of bacteriophages. 13th International Conference on the Molecular Biology and Pathogenesis of Clostridia (ClostPath). (Article publié).
• *Umansky A, *Garneau J, Peltier J, *Royer A, Fortier LC. (2023). Clostridioides difficileGenetic engineering of bacteriophages. 13th International Conference on the Molecular Biology and Pathogenesis of Clostridia (ClostPath). (Article publié).
• *Umansky A, Fortier LC. (2023). Clostridioides difficile Modification génétique des bactériophages de. Congrès Bactériologie intégrative: Symbiose - Pathogenèse - BiSP. (Article publié).
• *Saunier M, Kreis V, Fortier LC, Soutourina O. (2023). Clostridioides difficileStudy of a potential antiphage system of the "abortive infection" type regulated by a non-coding RNA in. 13th International Conference on the Molecular Biology and Pathogenesis of Clostridia (ClostPath). (Article publié).
• *Royer ALM, *Allen MM, *Umansky AA, *Garneau JR, *Ospina-Bedoya M, Kirk JA, Govoni G, Fagan RP, Fortier LC. (2022). Clostridioides difficileCaractérisation de la spécificité d’infection des phages de. ACFAS. (Article publié).
• *Royer ALM, *Allen MM, *Umansky AA, *Garneau JR, *Ospina-Bedoya M, Kirk JA, Govoni G, Fagan RP, Fortier LC. (2022). Clostridioides difficileSpecificity of phage-host interactions in. 71st Annual Conference of the Canadian Society of Microbiologists (CSM 2022). (Article accepté).
• *Chénard A, Ben Lagha A, *Garneau JR, Rivard N, Fortier LC. (2021). Modulation du virobiote intestinal lors de la colite induite par la perte d’expression de la phosphatase Shp-2 dans l’épithélium intestinal. Journée Phare. (Article publié).
• *Allen, MA; *Sbaghdi, T; *Garneau, JR; Gaucher, ML; Labrie, SJ; Fortier, LC. (2020). Clostridium perfringensIsolation and characterization of lytic phages infecting for veterinary applications in the avian industry. Phage Canada virtual meeting (National event). Canada, (Article accepté).
• Bouchard ME, Fortier LC, Rousseau E, Girard I. (2019). ***This poster won the first prize***Pathophysiologie des ulcérations chez les patientes porteuses de pessaire. Annual meeting of the association of gynecologists and obstetricians of Quebec (AOGQ) (Provincial event). (Article publié).
• *Garneau JR, Peltier J, Hamiot A, Tremblay Y, *Turcotte A, Dupuy B, Valiquette L, Monot M, Fortier LC. (2019). Clostridioides difficileImpacts of the phi027 prophage on the biology and virulence of the epidemic strain ribotype 027. Annual meeting of the Canadian Society of Microbiologists (CSM) (International event). (Article publié).
• *Jann J, Drevelle O, Dumont M, Bernier JL, Agbe H, Sarkar DK, Chen XG, Soucy G, Fortier LC, and Faucheux N. (2019). Development of biocidal surface technology based on anodized aluminum designed to fight nosocomial infections. 69th Canadian Chemical Engineering Conference (National event). (Article accepté).
• Bouchard ME, Fortier LC, Rousseau E, Girard I. (2019). Pathophysiology of ulcerations in women using pessary; experimental study. International Urogynecological Association (IUGA)/American Urogynecologic Society (AUGS) joint annual meeting (International event). (Article accepté).
• Fortier LC. (2018). C. difficile phages. 6th International Clostridium dificile Symposium (ICDS) (International event). (Article soumis).
• *Allen MM, *Ospina-Bedoya M, Kirk J, Fagan R, Govoni G, Fortier LC. (2018). Clostridium difficileThe surface layer proteinA (SlpA) serves as a general receptor for bacteriophage infection. 68th annual conference of the Canadian Society of Microbiologists (CSM) (International event). (Article soumis).
• Pasquier JC, Lewin A, *St-Pierre E, Gillet V, Fortier LC. (2017). Fecal transplants disturb length of pregnancy in a mouse model. 37th Annual pregnancy meeting of the Society of Maternal-Fetal Medicine (SMFM) (Jan 23-28). Las Vegas, NV, USA. (Article publié).
• *Garneau JR, Depardieu F, Fortier LC, Bikard D, Monot M. (2017). PhageTerm: a Fast and User-friendly Software to Determine Bacteriophage Termini and Packaging Mode using randomly fragmented NGS data. Centennial Celebration of Bacteriophage Research (April 24-26). Institut Pasteur, Paris, France. (Article accepté).
• *Garneau JR, Depardieu F, Fortier LC, Bikard D, Monot M. (2017). Phageterm: a fast and user-friendly software todetermine bacteriophage termini and packaging mode using randomly fragmented NGSdata. Annual meeting of the Canadian Society for Microbiologists (CSM) (June 20-23) Waterloo, ON, Canada. (Article accepté).
• Allard MJ, Guiraut C, Descoteaux M, Tremblay L, Lepage M, Fortier LC, Sébire G. (2017). StreptococcusPlacental group B infection: sex specific inflammatory response andautistic-like traits in male offspring. Meeting of the International Society for Autism Research (INSAR/IMFAR) (May 10-13). San Francisco, CA, USA. (Article accepté).
• *Larocque M, Fortier LC, Najmanovich R. (2016). Clostridium difficileIntegrative approach in drugs discovery pipeline applied to . ISMB/SigBio joint meetings, Orlando, FL, USA July 8-12. (Article publié).
• *Garneau JR, Monot M, Valiquette L, Fortier LC. (2016). Clostridium difficileProphage elements as a significant source of genetic diversity among epidemic R027 clinical isolates of . Annual meeting of the Canadian Society for Microbiologists (CSM). (Article publié).
• *Ospina-Bedoya M, Fagan R, Govoni G, Fortier LC. (2016). Clostridium difficileRole of the Surface Layer Protein A in bacteriophage infection. Annual meeting of the Canadian Society for Microbiologists (CSM). (Article publié).
• Abou Chakra CN, McGeer A, Labbé AC, Simor AE, Gold W, Muller MP, Devlin R, Powis J, Katz K, *Garneau JR, Fortier LC, Pépin J, Valiquette L. (2015). Clostridium difficileIndependent Risk Factors for Recurrence of Infection: ACanadian Multicenter Prospective Cohort. IDWeek. (Article publié).
• *Garneau JR, Abou Chakra CN, Labbé AC, McGeer A, Pépin J, Valiquette L, Fortier LC. (2015). ClostridiumdifficileRelationship between MLVA genetic types andclinical outcomes following infection by ribotype 027. 5th ICDS meeting. (Article publié).
• *Michaud A, *Smith-Peter E, Lafontaine DA, Fortier LC. (2015). Clostridium difficileThe riboswitch-controlled GMP synthase GuaA is important for survival andvirulence of and in a mouse model ofinfection. Annual meeting of the RiboClub. (Article publié).
• *Sekulovic O, Fortier LC. (2014). Clostridium difficileA first glance atphage-host interactions in . General meeting of the American Society for Microbiology (ASM. (Article publié).
• *Garneau JR, Abou Chakra CN, Fortier LC, Labbé AC, McGeer A, Pépin J, Valiquette L. (2014). Clostridium difficileAnalyse de l'impact des types génétiques bactériens MLVA sur les issues cliniques d'infection par ribotype 027. Annual meeting of the Association des Médecins Microbiologistes infectiologues du Québec - AMMIQ. (Article publié).
• Bordeleau E, Purcell EB, Paquette-D’Avignon M, Lafontaine DA, Fortier LC, Tamayo R, Burrus V. (2014). Cyclic-di-GMP signaling and type IV pili-mediated aggregation in Clostridium difficile. 114th General meeting of the America Society for Microbiology (ASM). (Article publié).
• Allard MJ, Bergeron J, Grbic D, Fortier LC, Poyart C, Sébire G. (2014). StreptococcusGroup B infection during gestation induces gender specific neurodevelopmentalimpairments. Joint Meeting of the 20th Biennial Meeting of the International Society for Developmental Neuroscience and the 5th Annual NeuroDevNet Brain Development Conference (ISDN, NeuroDevNet 2014). (Article publié).
• Allard MJ, Bergeron J, Fortier LC, Poyart C, Sébire G. (2014). StreptococcusGroup B infection during gestation leads to gender specific neurodevelopmental andbehavioural impairments. Annual Meeting of the Society for Neuroscience. (Article publié).
• *Garneau JR, *Sekulovic O, *Néron A, Fortier LC. (2014). Temperate phages of Clostridium difficile isolated from farm animals. 114th General meeting of the America Society for Microbiology (ASM). (Article publié).
• *Sekulovic O, Fortier LC. (2013). A First Glance at Phage-Host Interactions in Clostridium difficile. 8th International Conference on the Molecular Biology and Pathogenesis of the Clostridia – ClosPath. (Article publié).
• Bergeron J, Brochu ME, Deslauriers J, Grignon S, Fortier LC, Sébire G. (2013). Gestational exposure to inactivated Group B Streptococcus induced gender-dependent brain damage and autistic features in offspring. Pediatric Academic Societies/Eastern Society for Pediatric Research Annual Meeting. (Article publié).
• Bergeron J, Allard MJ, Deslauriers J, Grignon S, Sarret P, Fortier LC, Poyart C, Sébire G. (2013). Group B Streptococcus inflammatory response induced during gestation recapitulates perinatal injuries and subsequent behavioral impairments affecting premature human newborn such as autistic features in male offspring. Meeting of the Society for Neuroscience. (Article publié).
• Abou Chakra CN, Labbé AC, McGeer A, Simor A, Gold W, Devlin R, Katz K, Powis J, Fortier LC, Muller MP, *Garneau JR, Pepin J, Valiquette L. (2013). Risk factors for complications of Clostridium difficile Infection in a prospective multicentre cohort. IDWeek. (Article publié).
• Gebhart D, Scholl D, Vacin C, Fortier LC, Williams S, Govoni G. (2012). Diffocins: novel, high-molecular weight bacteriocins highly specific for Clostridium difficile. 4th International Conference on Clostridium difficile (4th ICDS). (Article publié).
• St-Pierre E, Lalonde Séguin D, Burrus V, Fortier LC. (2012). Inactivation of chemotaxis-associated genes increases flagellar motility in Clostridium difficile. 4th International Conference on Clostridium difficile (4th ICDS). (Article publié).
• Garneau JR, Valiquette L, Fortier LC. (2012). La sporulation de Clostridium difficile est inhibée par des concentrations sous-inhibitrices de tigecycline et de piperacillin-tazobactam in vitro. Annual scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Article publié).
• St-Pierre E, Pépin ME, Burrus V, Fortier LC. (2012). Rôle de la mobilité et du chimiotactisme dans la virulence de Clostridium difficile. Annual scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Article publié).
• Kelly M, Fortier LC. (2011). Antimicrobial activity of beta-bio 45% hops extract against Clostridium difficile NAP1/027 (Abstract #32532). 49th Annual Meeting of the Infectious Diseases Society of America - IDSA. (Article publié).
• Sirard S, Valiquette L, Fortier LC. (2011). Can the clinical outcomes associated with Clostridium difficile Infections (CDI) be predicted by bacterial genotype and phenotypes?. Annual meeting of the Association des Médecins Microbiologistes infectiologues - AMMI. (Article publié).
• Bergeron J, Girard S, Brochu ME, Fortier LC, Sébire G. (2011). Implication du Streptocoque de groupe B dans les lésions cérébrales périnatales. Annual scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Article publié).
• Gebhart D, Williams S, Fortier LC, Govoni G, Scholl D. (2011). Phage tail-like bacteriocins of Clostridium difficile. 7th International Conference on the Molecular Biology and Pathogenesis of the Clostridia (ClosPath). (Article publié).
• Bergeron J, Girard S, Brochu ME, Fortier LC, Sebire G. (2011). Role of gestational inflammation induced by group B streptococcus in perinatal brain lesions and subsequent cerebral palsy. 40th Annual Meeting of the Child Neurology Society. (Article publié).
• Néron A, Sekulovic O, Fortier LC. (2010). Diversité et biologie des bacteriophages de Clostridium difficile isolés de souches animales. Annual Pharmacology meeting, faculty of medicine of the Université de Sherbrooke. (Article publié).
• Pinard MM, Fortier LC. (2010). In vivo prophage induction in patients infected by Clostridium difficile. Viruses of Microbes meeting. (Article publié).
• Bergeron J, Girard S, Brochu ME, Fortier LC, Sébire G. (2010). Mise au point d’un modèle animal de paralysie cérébrale par exposition gestationnelle au Streptocoque de groupe B inactivé. Annual meeting of Pediatrics, Sherbrooke hospital center (CHUS). (Article publié).
• Sirard S, Valiquette L, Fortier LC. (2010). Peut-on prédire la sévérité des infections à C. difficile (ICD) en se basant sur le phénotype et le génotype bactériens ?. 39th scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Article publié).
• Sirard, S, Valiquette, L, Fortier LC. (2010). Peut-on prédire la sévérité des infections à C. difficile (ICD) en se basant sur l’analyse génotypique et phénotypique des souches bactériennes?. 78th Meeting of the ACFAS. (Article publié).
• Sekulovic O, Fortier LC. (2010). Prophage-enhanced toxin production in Clostridium difficile NAP1/027 lysogens. Viruses of Microbes meeting. (Article publié).
• Sirard S, Valiquette L, Fortier LC. (2010). Prédire la sévérité des infections à C. difficile : plus difficile qu’il n’y paraît !. Annual research meeting of the Université de Sherbrooke. (Article publié).
• Fortier LC, Matte I, Côté É, Asselin A-É, Asselin C, Piché A. (2009). Anti-apoptotic proteins Bcl-2/Bcl-XL protect from Clostridium difficile toxin A-induced cell death. 26th International Congress of Chemotherapy and Infection (ICC). (Article publié).
• Sekulovic O, Fortier LC. (2009). Impact des prophages sur la biologie de Clostridium difficile. 38th scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Article publié).
• Pinard MM, Fortier LC. (2009). La phagothérapie contre Clostridium difficile : une réalité ?. 38th scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Article publié).
• Mauler S, Pinard MM, Sekulovic O, Fortier LC. (2009). Les bactériophages contre C. difficile : réalité ou utopie ?. Annual research meeting of the Université de Sherbrooke. (Article publié).
• Haaber J, Moineau S, Fortier LC, Hammer K. (2008). AbiV, a novel abortive phage infection mechanism on the chromosome of Lactococcus lactis subsp. cremoris MG1363. 9th Symposium on Lactic Acid Bacteria. (Article publié).
• Pinard MM, Sekulovic O, Fortier LC. (2008). Les phages de Clostridium difficile : rôle dans la virulence et potentiel thérapeutique. 37th scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Article publié).
• Pinard MM, Sekulovic O, Fortier LC. (2008). Les phages de Clostridium difficile : rôle dans la virulence et potentiel thérapeutique. Annual research meeting of the Université de Sherbrooke. (Article publié).
• Mauler S, Fortier LC. (2008). Potentiel thérapeutique des endolysines pour prévenir ou traiter les infections à Clostridium difficile. 37th scientific meeting of the faculty of medicine of the Université de Sherbrooke. (Article publié).
• Mauler S, Fortier LC. (2008). Potentiel thérapeutique des endolysines pour prévenir ou traiter les infections à Clostridium difficile. Annual research meeting of the Université de Sherbrooke. (Article publié).

Propriétés intellectuelles

Brevets

• GAUDREAU S, CLOUTIER M, FORTIER LC, LEDUC F, Tremblay M, VERONNEAU S, GBRIC D, LARRIVEE JF. (2016). C. difficile antibodies directed thereto, and target for the treatment of humans and other animals intoxicated with at least one bacterial toxin A and/or B. 62118450. Canada. (Délivré).

Autres contributions

Cours enseignés

• Virology / Virologie. VIR 500. (2022-01-01).Université de Sherbrooke. Canada. (2CR).
• Virology lab / Travaux pratiques en virologie. VIR 515. (2020-09-01).Université de Sherbrooke. Canada. (1CR).
• Microbiologie en pharmacologie. MCB103. (2016-09-01).Université de Sherbrooke. Canada.
• Le microbiome dans la physiologie, l'immunologie et le métabolisme de l'hôte. MCR717. (2016-01-01).Université de Sherbrooke. Canada.

Gestion d'évènements

• Co-chair. (2019) 69th annual meeting of the Canadian Society of Microbiologists (CSM). (Conférence).
• Co-organizer. (2019) Annual scientific retreat of the Inflammation & Pain research axis of the CHUS research center. Club de Golf de Sherbrooke, (May 8) Sherbrooke, QC, CA. (Conférence).

Activités de collaboration internationale

• Principal investigator and Collaborator. France. My team has been collaborating for several years with two groups in France, one at the Institut Pasteur in Paris (Marc Monot, David Bikard and Bruno Dupuy), and the other one in Université Paris-Saclay (Olga Soutourina). My collaboration involves phage work related to CRISPRs, toxin/antitoxin systems, and phage-host interactions in C. difficile. One of my former PhD students, Julian Garneau was co-supervised by Marc Monot at Pasteur. He has done a 9 months training in Paris to learn new skills in bioinformatics. Julian now continues a postdoc with Marc Monot and we will keep working in close collaboration. With Olga Soutourina, we have recruited two doctoral students in cosupervision between our institutions in September 2021.
• Principal investigator and Collaborator. Royaume-Uni. Clostridioides difficileI am collaborating with Robert P. Fagan from the University of Sheffield. He is an expert in the structure of the cell surface and cell wall composition of . He studies, among others, the interaction between phage tail-like particles, whole phage particles, and host receptors at the surface of . I collaborate with his group to pursue the characterisation of the detailed interaction between phages and C. difficile. Our work involves using various C. difficile mutants and plasmid constructions that R. Fagan developed, and I perform all the phage work.
• Collaborator. États-Unis d'Amérique. I have participated in a research collaboration with the private company AvidBiotics in South San Francisco (CA, USA). They have started studying phage tail-like particles that I had identified and described earlier in a paper (Fortier and Moineau, AEM 2007). I shared with them bacterial strains, protocols and my expertise. I also performed electron microscopy analyses and contributed to the preparation of the manuscript that we published together in 2012 (Gebhart et al, J. Bacteriol. 2012).
• Principal investigator. Royaume-Uni. We collaborated with the group of Neil Fairweather on the study of the cell wall associated protein CwpV in C. difficile. They shared with us various constructions of CwpV and antibodies and we shared our recent research results with them. They were co-authors of a publication with us (Sekulovic et al, Mol. Microbiol. 2015).

Présentations

• Fortier LC. (2024). Engineering bacteriophage-based therapeutics to fight multidrug resistant bacteria. Invited talk by Sanofi Vaccines (Virtual presentation on Zoom with Sanofi people from Europe, USA and Canada divisions). Canada
• Fortier LC. (2022). Phagothérapie des infections à Clostridioides difficile: état des lieux. ACFAS annual meeting (International). Virtual, Canada
• Fortier LC. (2021). Importance du microbiome et du virome en obstétrique/gynécologie. Grand Round seminar series (presented to medical doctors and clinical researchers). Sherbrooke, Canada
• *Allen, MM (Speaker); *Sbaghdi, T; *Garneau, JR; Gaucher, ML; Labrie, SJ; Fortier, LC. (2020). Isolation and characterization of lytic phages infecting Clostridium perfringens for veterinary applications in the avian industry. Phage Canada (virtual meeting - national). Canada
• *Jann J, Drevelle O, Dumont M, Bernier JL, Agbe H, Sarkar DK, Chen XG, Soucy G, Fortier LC, Faucheux N. (2019). Development of biocidal surface technology based on anodized aluminum designed to fight nosocomial infections. ***Selected by the organizing committee for an oral presentation. 69th Canadian Chemical Engineering Conference. Halifax, Canada
• *Garneau JR, Peltier J, Hamiot A, Tremblay Y, Turcotte A, Dupuy B, Valiquette L, Monot M, Fortier LC. (2019). Impacts du prophage phi027 dans la biologie et la virulence de la souche épidémique Clostridioides difficile ribotype R027. Annual scientific retreat of the Inflammation & Pain research axis of the CHUS research center. Sherbrooke, Canada
• Fortier LC. (2019). Phage-host interactions in Clostridioides difficile. Invited speaker for seminar series at Texas A&M, Department of Biology. Texas, États-Unis d'Amérique
• Fortier LC. (2019). Phage-host interactions in the human pathogen Clostridium difficile. Phage Fest - 10th anniversary William & Mary University, Department of Biology, Integrated Science Center. Williamsburg, États-Unis d'Amérique
• Fortier LC. (2018). C. difficile phages. 6th International Clostridium difficile symposium (ICDS). Bled, Slovénie
• Fortier LC. (2018). Clostridium difficile et ses bactériophages. Invited speaker at Université Laval. Québec, Canada
• Fortier LC. (2017). Interactions phages-hôte chez Clostridium difficile. Université Laval - Conférence invitée. Québec, Canada
• Fortier LC. (2016). Interactions phages-hôte chez la bactérie pathogène Clostridium difficile. Conferences of the department of Immunology of the faculty of medicine of the Université de Sherbrooke. Sherbrooke, Canada
• Fortier LC. (2016). La prescription des phages. French conference in medicine of Moncton. Moncton, Canada
• Fortier LC. (2015). Le développement d'un nouvel antibiotique: de l'idée à la clinique. CursUS-Santé. Sherbrooke, Canada
• Fortier LC. (2015). Phage-host interactions in Clostridium difficile. Invited speaker at the Institut Pasteur in Paris, France. Paris, France
• *Sekulovic O, *Ospina Bedoya M, Fairweather N, Fortier LC. (2015). The phase-variable cell wall protein CwpV confers phage resistance to Clostridium difficile. *This abstract was selected for an oral presentation by the review committee. 5th ICDS meeting. Bled, Slovénie
• Fortier LC, Déziel E, Weiss K, Behr M. (2014). "Les superbactéries, doit-on s'en préoccuper?" Superbugs, should we be preoccupied? I was invited as a microbiology expert (along with 3 other microbiologists) to discuss this topic with the public. Les grands rendez-vous scientifiques du Musée de l'Institut Armand-Frapier. Laval, Canada
• *Sekulovic O, Fortier LC. (2014). A first glance at phage-host interactions in Clostridium difficile. * This abstract was selected for an oral presentation by the review committee, and won the Gisela Mosig prize for best abstract. General meeting of the American Society for Microbiology (ASM). Boston, États-Unis d'Amérique
• Fortier LC. (2014). Développement d'une plateforme pour l'étude du microbiote intestinal. Technological conferences of the research axis in inflammation and pain of the CHUS research center. Sherbrooke, Canada
• Fortier LC. (2014). Impact des antibiotiques sur la susceptibilité aux infections à Clostridium difficile: une approche intégrative. 56e réunion annuelle du Club de Recherche Clinique du Québec. Mont Gabriel, Canada
• Lafontaine DA, Marsault E, Malouin F, Fortier LC. (2014). The guanine riboswitch as a target for the treatment of C. difficile and S. aureus infections. Second presentation in front of potential investors (Amorchem, Neomed and MSBiV). Montréal, Canada
• Bordeleau E, Purcell E, Lafontaine DA, Fortier LC, Tamayo R, Burrus V. (2013). Cyclic-di-GMP riboswitch-controlled type IV pili-mediated aggregation in Clostridium difficile. 8th International Conference on the Molecular Biology and Pathogenesis of the Clostridia – ClosPath. Palm Cove, Australie
• Fortier LC. (2013). Impact des antibiotiques sur la susceptibilité aux infections à Clostridium difficile: une approche integrative. First annual meeting of the Research Center on Inflammation and Cancer of the Université de Sherbrooke (CRICUS). Sherbrooke, Canada
• Fortier LC. (2013). Pathogenèse des infections à Clostridium difficile et développement de nouveaux antibiotiques. Annual research forum of the faculty of medicine of the Université de Sherbrooke. Magog, Canada
• Fortier LC. (2013). Phage-host interactions in the human pathogen Clostridium difficile. Seminars series at Memorial University. St-John's, Canada
• Lafontaine DA, Marsault E, Malouin F, Fortier LC. (2013). The guanine riboswitch as a target for the treatment of C. difficile and S. aureus infections. First presentation in front of potential investors (Amorchem, Neomed and MSBiV). Montréal, Canada
• Fortier LC. (2012). Genetic diversity of Clostridium difficile and novel therapeutic strategies. Invited speaker at ViroPharma Inc. Exton, États-Unis d'Amérique
• Fortier LC. (2012). Pathogenesis of Clostridium difficile infections and novel therapeutic strategies. Invited speaker at AvidBiotics Inc. South San Francisco, États-Unis d'Amérique
• Fortier LC. (2012). Pathogénèse des infections à Clostridium difficile. Conférences en microbiologie et en biotechnologie. Sherbrooke, Canada
• (2011). Pathogenesis of Clostridium difficile infections and development of novel antimicrobial agents. Invited speaker for the annual CIHR Infection and Immunity consulting committee. Sherbrooke, Canada
• Garneau JR, Valiquette L, Fortier LC. (2011). Sub-inhibitory concentrations of tigecycline inhibit sporulation of Clostridium difficile in vitro. 7th International Conference on the Molecular Biology and Pathogenesis of the Clostridia – ClosPath. Aymes, États-Unis d'Amérique
• Sirard S, Valiquette L, Fortier LC. (2010). Peut-on prédire la sévérité des infections à C. difficile (ICD) en se basant sur l’analyse génotypique et phénotypique des souches bactériennes?. Annual Meeting of the Association des Médecins Microbiologistes Infectiologues du Québec (AMMIQ-JAFA). Québec, Canada
• Fortier LC, Sekulovic O, Meessen-Pinard M. (2010). The multiple facets of bacteriophages and their role in the diversity and virulence of C. difficile. 3rd International Clostridium difficile symposium. Bled, Slovénie
• Mulhbacher J, Brouillette E, Malouin F, Fortier LC, Lafontaine DA. (2009). Guanine riboswitch as a target for new antibiotics family. Invited seminar at the faculty of medicine of the U. of Montreal. Montreal, Canada
• Sekulovic O, Fortier LC. (2009). Impact des prophages sur la biologie de Clostridium difficile. Conferences of the infectious diseases research group of the Centre de recherche clinique Etienne-LeBel of the Faculty of medicine of the Université de Sherbrooke. Sherbrooke, Canada
• Sirard S, Valiquette L, Fortier LC. (2009). Infections à C. difficile: quand C. difficile, ce n’est jamais simple!. Conferences of the infectious diseases research group of the Centre de recherche clinique Etienne-LeBel of the Faculty of medicine of the Université de Sherbrooke. Sherbrooke, Canada
• Mulhbacher J, Fortier LC, Malouin F, Lafontaine DA. (2009). Novel antibioswitches as selective inhibitors of guanine-related metabolic pathways. 10th annual Eastern Ribo-club Opening Session. Magog, Canada
• Sekulovic O, Meessen-Pinard M, Fortier LC. (2009). Prophage-enhanced toxin production in Clostridium difficile NAP1/027 lysogens. "This abstract was selected for a slide presentation by the review committee". 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, États-Unis d'Amérique
• Mulhbacher J, Fortier LC, Malouin F, Lafontaine DA. (2009). Riboswitch guanine: nouvelle cible pour les antibioswitches. Conferences of the infectious diseases research group of the Centre de recherche clinique Etienne-LeBel of the Faculty of medicine of the Université de Sherbrooke. Sherbrooke, Canada
• (2009). Rôle des bactériophages dans l’évolution et la virulence de Clostridium difficile. Conferences of the infectious diseases research group of the Centre de recherche clinique Etienne-LeBel. Sherbrooke, Canada
• Mulhbacher J, Heppell B, Moisan H, Malouin F, Fortier LC, Lafontaine DA. (2008). Guanine riboswitch inhibitors as promising new antibiotics family against S. aureus and C. difficile. 10th annual Ontario-Québec Biotechnology meeting. Sherbrooke, Canada
• Mulhbacher J, Heppell B, Moisan H, Malouin F, Fortier LC, Lafontaine DA. (2008). Guanine riboswitch inhibitors as promising new antibiotics family against S. aureus and C. difficile. Conferences of the Ribo-club. Magog, Canada
• Mulhbacher J, Heppell B, Moisan H, Malouin F, Fortier LC, Lafontaine DA. (2008). Guanine riboswitch inhibitors as promising new antibiotics family against S. aureus and C. difficile. RNA meeting. Berlin, Allemagne
• Fortier LC. (2008). Potential of phage therapy to fight Clostridium difficile infections. Eliava-2008: Phage biology, ecology and therapy meeting. Tbilisi, Géorgie
• Mauler S, Fortier LC. (2008). Potentiel thérapeutique des endolysines pour prévenir ou traiter les infections à Clostridium difficile. Conferences of the infectious diseases research group of the Centre de recherche clinique Etienne-Le Bel of the Faculty of medicine of the Université de Sherbrooke. Sherbrooke, Canada